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Abstract The search for isoform-specific enzyme inhibitors has 
been the focus of much recent research effort. Towards this goal, 
human recombinant cyclooxygenase-2 (EC 1.14.99.1, prosta-
glandin H synthase) was expressed in insect cells and purified to 
>98% purity. Recombinant enzyme was characterized both by 
physical methods and activity measurements and shown to be 
fully active with kinetic properties similar to native COX-2 and 
COX-I. After detergent extraction, the enzyme had hydrody-
namic properties indistinguishable from native bovine COX-I and 
corresponded to the enzyme dimer as measured with size-exclu-
sion chromatography. Peptide mapping via Lys-C protease iden-
tified a site of N-Iinked glycosylation and the aspirin covalent 
modification site. In the presence of heme, aspirin-specifically 
acetylated Ser-516. The enzyme will be suitable for biophysical 
studies and may lead to isoform-specific enzyme inhibitors. 
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I. Introduction 
The recent discovery [1,2] and cloning [3-8] of an inducible 
isoform of cyclooxygenase (prostaglandin G/H synthase) has 
initiated a reinvestigation of inflammatory prostanoid biosyn-
thesis. We and several others [8-10] have put forward a model 
III which the constitutive form of cyclooxygenase (COX-I) 
plays a key role in cellular housekeeping functions while the 
inducible form (COX-2), when up regulated by mediators, such 
as IL-IfJ or TNF-a, produces pro-inflammatory amounts of 
cyclooxygenase products during an inflammatory response. 
Most non-sterOidal anti-inflammatory drugs (NSAIDs) are 
known to inhibit both isoforms of cyclooxygenase with only 
modest selectivity for one isozyme. The model presented previ-
ously, however, posits that drugs which are selective for COX-2 
might give the anti-inflammatory benefits of NSAIDs while 
avoiding their deleterious side-effects. These side-effects, which 
include gastric ulceration and renal insufficiency, can reasona-
bly be ascribed to inappropriate inhibitIOn of COX-I. There-
fore, the design of COX-2-specific inhibitors has attracted con-
siderable interest among enzymologists and molecular pharma-
cologists. 
Exploitation of the enzymatic and structural differences be-
tween the COX-I and COX-2 isoenzymes constitutes one strat-
egy to develop COX-2-specific inhibitors [11-13]. Structural 
informatIOn about COX-I [14] indicates that the amino acid 
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residues which are involved in binding heme and fatty acid 
substrates are highly conserved in the COX-2 sequence. The 
enzymologic properties of COX-I are well-studied, as are the 
properties of certain COX-I inhibitors. For COX-2, no struc-
tural information has been revealed and the enzymologic prop-
erties have been investigated only minimally. 
Whereas COX-I is known to be covalently modified by aspi-
rin at Ser-530 [14-17], the site of covalent modification of 
COX-2 has not yet been definitively demonstrated (see also 
Lecomte et al. [18]). Aspirin inhibited prostaglandin synthesis 
III whole cells or in microsomal assays using native or recombi-
nant enzymes [10,14,18-20]. However, COX-2 was shown to be 
different than COX-I in these systems as it caused an increased 
production of an alternate product 15-HETE [18,20-23]. In this 
study, we employed recombinant human COX-2 produced in 
the baculovirus/insect cell expression system and purified by a 
two-step process. The resulting enzyme has been characterized 
for substrate preferences, heme stoichiometry and kinetic prop-
erties. Using this well-characterized enzyme and peptide map-
ping strategies, aspirin was demonstrated to label Ser-516 spe-
cifically and effiCiently. The site is analogous to residue Ser-530 
of COX-I. 
2. Materials and methods 
2 I. Chenllcals 
Chemicals obtamed were ram semmal vesicle COX-I and sheep 
placental COX-2 from Cayman (Ann Arbor, MI), Lys-C, endoglycosi-
dase F and en do glycosidase H from Boehnnger (Indianapolis, IN), 
matenal for SDS-PAGE and Western analYSIS from BIORad 
(Richmond, CAl, chemllummescent detectIOn reagents from Amer-
sham (Little Chalfont, UK). Normal-phase chromatography media was 
from PharmacJa (Uppsala, Sweden), reverse-phase columns from 
Alltech (Deerfield, IL) and HPLC equipment from Waters (Medford, 
MA) All other chemicals were the highest quality available and gener-
ally obtained from Sigma (St. Louis, MOj. 
2.2. COX-2 purTjzcatwll 
All procedures were performed at 4°C unless otherWise mdlcated. 
The baculovlrus expression system was a modification of the system 
described by Miller et a!. [24]. HlghFlve cells (Invitrogen) were cultured 
m I-I spmner flasks (Techne) m Grace's complete msect media contam-
ing 5% fetal bovine serum (Glbco) until the cell density was I.S--
22 X 106 cells/m!. Cells, whose viability was at least 9S% at this stage, 
were mfected with baculovlrus [24] at a multipliCity of infection (MOl) 
of 5 and harvested 72 h later. To obtain microsomal membranes, the 
pellets from 2.5-1 cultures were thawed and resuspended in a total 
volume of 100 ml buffer A (100 mM KHP04, pH 7.2, 0.3 mM di-
ethyldlthlOcarbamate, I mM EDTA). The suspension was somcated at 
the maximum settmg of a micro tip probe (Branson Sonifier 250) 6 x 
for 5 s with 30-s intervals for cooling. Sonicates were spun at 1000 x g 
for 10 min and the pellets collected and the SOlllcatlOn procedure re-
peated. The combmed supernatants were spun at 150,000 x g for 45 mm 
and the waxy pellets resuspended With 30 strokes of a Dounce homog-
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enizer with tight-fitting pestle. Microsomal suspensions were aliquoted 
and frozen pending punfication. 
A microsome pellet correspondmg to 2.5 I of cell culture and weigh-
ing -10 g wet weight was used for a typical purification. Microsomes 
were centnfuged at 200,000 x g for 20 min and resuspended into 200 
ml ofTECP buffer (50 mM Tns, pH 8.0.1 mM EDTA. 0.1 mM DDC 
0.1 M sodium perchlorate). The microsomes were agam centrifuged at 
200,000 x g for 20 min and the pellet resuspended into 100 ml of 2% 
,O-octyl glucoside (BOG) in TE (20 mM Tris. pH 7.4, 0.1 mM EDTA) 
containing anti-proteases (pepstatm. aprotinin, leupeptin, chymostatin: 
all present at 1 ,ug/ml). The mixture was incubated with gentle shaking 
for I h then centrifuged at 200,000 x g for I h. The supernatant was 
diluted with TE to a final BOG concentration of 0.9% and then was 
loaded onto a DEAE-Sepharose (Fast Flow) column (I x 20 cm) equil-
Ibrated with TEG (TE with 0.9% BOG) + 0.1 M NaCI The column 
was run at a flow rate of I mllmin with a linear gradient of NaCI from 
0.1 to 0.35 Mover 60 mm and COX-2 eluted at -0.20 M. The active 
fractIOns were pooled, adjusted to 2 mM calcium chlonde and mixed 
in batch for 1.5 h with 20 ml of Lentil-Lectin-Sepharose (Pharmacia) 
equilibrated with a buffer of TEG supplemented with 2 mM calcium 
chloride and 150 mM NaCI. The gel was washed with 3 washes of 10 
vols. of buffer, packed into a small disposable column and COX-2 
eluted at room temperature With 0 5 M :x-methyl pyranoslde in the same 
buffer. The active pool was concentrated with an Amicon Centricon-30 
membrane. separated mto aliquots and frozen at -80°C. 
For size-exclusion chromatography. a 90-ml Sephacryl S300 column 
(Pharmacia) was used in a buffer of TEG containmg 0.15 M NaCl 
SDS-PAGE analYSIS was performed using standard procedures With 
BioRad 7.5. 10 or 12% acrylamide gels Gels were either stained with 
Coomassle brilliant blue or analysed by Western analysis using rabbit 
polyclonal antibodies either anti-chicken PGHS-2 (Oxford Biomedical 
Research, No. PG25) or anti-COX-2 peptide (Oxford Biomedical Re-
search. No. PG26). Purity of COX-2 samples were judged by reverse-
phase HPLC using a C4 Alltech column and a 30-70% acetonitrile 
gradient over 30 min and monitonng OD at 210 nm. 
:: 3 Peptide mapplllg 
COX-2 was treated With endoglycosldase F (a mixture of 6 U en-
do glycosidase F and 150 U glycopeptidase F per Vial; Boehnnger 
Mannheim product 878740) overnight at 37°C in a total volume of 0.1 
ml contaming 0.3 U of the glycosidase and 100,ug COX-2. For digestIOn 
of native (non-denatured) COX-2, the buffer was 0.25 M sodIUm ace-
tate, pH 6.5, 20 mM EDTA and 10 mM 2-mercaptoethanol. For diges-
tion of denatured COX-2, the same buffer was supplemented with 10 
mg/ml SDS and then diluted with 60 mg/ml NP40 as per the manufac-
turer's instructions. Endoglycosldase H ""as used according to the man-
ufacturer's recommendations. COX-2 was treated with endoprotemase 
Lys-C (BM No. 1047 825) after reduction and carboxyamidatlOn. 
COX-2 was diluted with 2 vols. of UBET buffer (0.1 M NH4CO), I 0 
mM EDTA, 0.02% Tween 20. 25 mM methylamme, 9.0 M Urea), DTT 
was added to a final concentration of 10 mM and the mixture was 
incubated m the dark at 37°C for 30 min. Iodoacetamide was added 
to a final concentratIOn of 20 mM and the mixture kept at 37°C for an 
additIOnal 30 min. Lys-C was added to this reduced and alkylated 
COX-2 to a ratIO of \:100 and mcubated at 37°C for 4 h. To stop the 
Lys-C digestIOn, 1110 vol. of 10% TFA was added and the mixture 
analysed by HPLC using an Alltech macrosphere 300 C4 column With 
a 45 mm linear gradient from 15% B (90% acetonitnle. 0.09% TFA)/ 
Table I 
PurificatIOn of recombinant COX-2 
FractIOn Total actlVlty Total protein 
(,umollmin) (mg) 
Mlcrosomes 494 511 
Detergent extract 444 III 
Insoluble mlcrosomes 6 275 
DEAE pool 300 52 
Purified 188 8 
Lentil-Lectin unbound 71 28 
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85% A (5% acetomtrile. 0.9% TFA) to 45% B/55% A. Detectivn was 
performed by monitonng the eluent for absorption at 210 nm with a 
Waters 481 UV detector and momtoring fluorescence emission at 350 
nm with a Waters 470 fluorescent detector using an excitation wave-
length of 280. Samples were dned in a Savant rotary evaporator and 
analysed by either Harvard Microsequence Facility in Boston (MA) 
(mass spectral analYSIS) or at Commonwealth Biotechnology m 
Richmond (VA) (sequencmg. amino acid analysis). 
24. Miscellaneous methods 
Cyclooxygenase activity was determined by an oxygen uptake assay 
using a Yellow Spnngs Instruments polarographic electrode (Yellow 
Spnngs. MD) with modifications of a reported method [25] Assays 
were done at 37°C in 0.1 M Tris. 4 mM EDTA. 0.05% Tween and 2 
mM phenol. pH 8.0. Enzyme samples were preincubated on Ice with 50 
,liM hematin and activation was mitiated by injection of the enzyme into 
3 ml of buffer con taming arachidonic acid. Oxygen consumption was 
evaluated usmg a program (Labview, NatIOnal Instruments) to measure 
maximal velOCity. Vopt ' as nmol oxygen/minIm!. Peroxidase was meas-
ured as described prevIOusly [24]. Heme titration was performed as 
described by Kulmacz and Lands [26]. 
Radiolabeled aspirin was made from ['H]acetic anhydride (370 mCi/ 
mmol; Amersham) based on the procedure of Ali [27] and purified twice 
by reverse-phase HPLC using a Metachem Intersil ODS-2 column and 
a mobile phase of 74:25 I (v/v/v) methanol:water:acetic acid. Aspirin 
was stored m ethanol after HPLC purification. Aspirin labeling was 
performed using a modificatIOn of the method used by Chen et al. [19]. 
To a tube con taming 16,uM COX-2 (1.2 mg in 500,u1 buffer), 20,uM 
hematin and either 0 or I mM flurbiprofen, eH]asplrin was added to 
give a final concentration of 3 mM. After incubation at room temper-
ature for 30 min, unreacted aspirin was removed by a desaltmg NAP-5 
column (Pharmacia) equilibrated with 20 mM Tns, pH 8.0, I mM 
EDTA, 0.9% BOG buffer. Aliquots of enzyme samples were checked 
10 oxygen uptake assays. Labeled enzyme was further evaluated by 
peptide mapping. Protem was determined by Lowry analYSIS using BSA 
as a standard and confirmed by amino aCid analysis (Commonwealth 
Biotechnologies, Richmond, VA). 
3. Results 
The baculovirus expression system previously described was 
further refined by the use of HighFive insect cells which re-
sulted in a 2-fold higher level of expression of COX-2 then 
previously reported [24]. Purification of the enzyme (Table I) 
was achieved folloy. ing detergent extraction of the microsomes. 
Inspection of SDS-PAGE gels of the purification steps (Fig. I) 
revealed that the enzyme was visible in the crude microsomal 
fraction as a broad band of 73 kDa which represented -4% of 
the total protein. BOG detergent was effective in extracting the 
enzyme from microsomes with good recovery of activity and 
with a noticeable enrichment of the 73-kDa band as Judged by 
SDS-PAGE. A 68-kDa band was apparent in the non-extracted 
microsomal fraction (lane 2, Fig. la) which was recognized by 
anti-COX-2 antibodies using Western analysis (Fig. I b). Since 
SpeCific Recovery Punfication enrichment 
activity (%) (fold) 
I 100 I 
4 90 4 
0 I 0 
6 61 6 
25 38 26 
2 14 3 
PunficatlOn COX-2 from insect cells IS described m Section 2. Samples from each step were collected and analysed for protein by Lowry assay and 
for COX-2 activity by oxygen uptake (Section 2). SpeCific activity is from the oxygen consumplion assay. The results are an average of four 
preparations with generally good reproducibility between runs. PeroXidase assay (not shown) gave results Similar to oxygen consumptIOn results. 
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Fig 1 SDS-PAGE and Western analysis of COX-2 purified from 
baculovlrus-infected HighFive cells. Recombinant COX-2 was purified 
from Insect cells (Section 2) as outlined In Table I. (A) Purification 
fractIOns were run on a 12% SDS-PAGE gel then stained by Coomassie 
brilliant blue. Lane L crude mlcrosomes; lane 2. pellet after detergent 
extraction; lane 3. soluble phase of detergent extracted micro somes; 
lane 4. p001 from DEAE-Sepharose column; lane 5. Lentil-Lectin-
Agarose-punfied enzyme. The punfied enzyme in this preparation ap-
pears as a major band With a molecular weight of 73 kDa and a minor 
COX-2 band at 65 kDa (see text). (B) Identification of two COX-2 
species In nllcrosomes: three samples were run on 12% SDS-PAGE gels 
and tested: left. crude micro somes; center. detergent insoluble micro-
some pellets; and nght detergent extracts. The analysis was done either 
by staining gels With Coomassie brilliant blue (left) or by Western 
analysis with a COX-specific antibody (right). The two major bands of 
COX-2 are indicated as a 73-kDa band extracted by detergent and a 
68-kDa Insoluble band. (Cl Endoglycosidase treatment of COX-2: pu-
rified enzyme was treated with endoglycosidase F and run on a SDS-
PAGE gel and stained with Coomassie bnlliant blue. Lane I was pun-
fied COX-2 control. lane 2 was COX-2 treated with endoglycosidase 
F In non-denaturing buffer and lane 3 was COX-2 treated with endogly-
cosldase F In a denaturing buffer containing SDS (SectIOn 2). In thiS 
preparation. both bands of COX-2 shift to lower molecular weight; the 
73 kDa shifting to 68 kDa and the minor 65 kDa shifting to 63 kDa. 
See the test for details The relative positIOn for molecular weight 
standards IS Indicated In the figure as molecular weight x 10-3. 
the band is not extracted from the microsomes by BOG and 
since no activity remains in the extracted membranes, the pro-
tein presumably represented an improperly folded or denatured 
COX-2 fraction. The non-extracted band has the same migra-
tion as COX-2 which had been treated with endoglycosidase to 
remove N-linked carbohydrate (see below). The overall yield 
from microsomes to pure enzyme was -40%. It was essential to 
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maintain the detergent concentration at 0.9% in order to pre-
vent contaminating proteins from adhering to COX-2 and to 
prevent the enzyme from aggregating. The enzyme was stored 
at -80°C and little loss in activity was noticed over 6 months. 
COX-2 activity migrated on a S300 Sephacryl size-exclusion 
column (Fig. 2, tubes 27-32) in a manner indistinguishable 
from native COX-I (not shown) and similar to an aldolase 
standard (molecular weight 154 kDa). As discussed earlier 
[19,28], this migration corresponds to an enzyme dimer. Some 
higher molecular weight material eluted at the void volume 
(Tube 20-22). Rechromatography of the dimer pool (not 
shown) gave a profile similar to the original column run, con-
taining both dimer and higher aggregate. The result under-
scores the tendency of COX-2 to aggregate even in detergent. 
Upon storage of enzyme samples at 4°C for up to I week, 
higher molecular weight bands became evident by SDS-PAGE. 
The slight tailing shoulder of the dimer peak in Fig. 2 may 
represent a small fraction of monomeric COX-2 and this tail 
was similarly evident upon rechromatography. indicating it was 
created from the dimer dissociating into monomers during or 
before the column run. Enzyme activity co-migrated principally 
with the dimer peak and a slight activity was seen in the higher 
molecular weight peak. 
Sequence analysis of the purified COX-2 gave the predicted 
N-terminal of Ala-Asn-Pro-Cys-, indicating that the 17 amino-
acid signal sequence had been efficiently removed. From the 
SDS-PAGE analysis we estimate the enzyme to be -98% pure. 
The chief visible contaminant (typically < 5% of the major 
band) was a band which ran just below the main COX-2 band. 
has an approximate molecular weight 65 kDa and is likely to 
be a proteolytic degradation product produced during purifica-
tion. Endoglycosidase treatment of purified COX-2 with either 
endoglycosidase F or H resulted in a protein which migrated 
considerably faster as judged by mobility on SDS-PAGE (Fig. 
Ic) and having an approximate molecular weight of68 kDa. (It 
is worth noting that the resulting band co-migrated with the 
COX-2 material not extracted by detergent from micro somes 
as seen in Fig. la, lane 3.) When COX-2 was treated with 
endoglycosidase F either in buffer or buffer supplemented with 
Fig 2 Size ExclUSion Chromatography 
00280 
Vo 154 67 V, Vop! 
0006 ... ... ... ... 
0005 80 
0004 60 
0003 
40 
0002 
20 
0001 
10 60 
Fig. 2. S300 Sephacryl SIZe-exclusion chromatography ofCOX-2. After 
punficatlOn of COX-2 by Lentil-Lectin-Agarose chromatography. the 
sample was concentrated with an Amicon filtration deVice then the 
enzyme was passed through a S300 Sephacryl gel filtratIOn column. 
Fractions were analysed for activity as described in section 2. Activ-
Ity IS expressed In the bargraph as Fop,/IO,u1 of sample (nmol/min) 
ActiVity corresponded to the main peak with slight actlVlty aSSOCiated 
With the high molecular weight peak. The late-running peak IS probably 
non-protein as no activity migrated With thiS peak. 
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Table 2 
Peptide mapping of COX-2 
Predicted Sequence Length Mass Actual Fluorescence Sequence Mass Assignment 
fragment fragment 
FI N-41 24@ 2645@ A 1793* F32 
F2 42~64 GPI 23 2642 B 
F3 65~68 4 520 C 4473* F30/31 
F4 69~82 14 1668 D 
F5 83~123 w 41 4735 E 
F6 124--152 GP2.w 29 3225 F w (FI8) 
F7 153~154 2 203 G w F6 = GP2 
F8 156~166 II 1199 H w 
F9 167~172 6 798 I w 3999 F22 
FlO 173~197 25 3021 J w 3077 FI2 
Fll 198~201 4 500 K w (F5 or F18/19) 
FI2 202~229 28 3078 L w 
F13 230~234 5 676 M PIDP+ EMSAE FlO + F28/29 
FI4 235~237 3 318 N w GLMGN F30/(7) 
FI5 238~239 2 277 0 EMSAE F28/29 
FI6 240~253 14 1654 P w 6249* F30/31/32 
FI7 254--303 w 50 5800 Q 
FI8 304--328 w 25 2968 R EMSAE F28/29 
FI9 329~344 16 1948 
F20 345~346 2 259 
F21 347~355 9 1122 *Carboxyamidated 
F22 356~387 w 32 4000 @After processmg 
F23 388-432 GP3 45 5126 
F24 433-445 13 1478 
F25 446-454 9 1234 
F26 455-459 5 694 
F27 460-471 12 1429 
F28 472-497 26 2882 
F29 498~518 21 2262 
F30 519~532 w 14 1539 
F31 533~559 27 2838 
F32 560--575 16 1737 
F33 576-598 GP4 23 2402 
F34 599~604 6 734 
Left: theoretical charactenzatlOn of a Lys-C peptide map of COX-2. Pep tides containmg tryptophan reSidues are indicated with a 'W'. Right: peptides 
identified in Fig. 3 were collected and analysed by vanous methods mc1udmg amino acid analysIs, peptide sequencing and mass spectral analysis 
(MS) using electro spray or laser desorption. Peaks which could be positively identified (sequencmg and MS) are noted in the last column. Certam 
peaks were tentatively identified either usmg MS alone or because parent ion mass was> 2% from the predicted values and these peaks are listed 
in parentheses. Fragments of mcomplete digestIOn are mdlcated with a 'f' between peptides. Fragment F28/29 is noted in three peaks, none of which 
were fluorescent and, therefore, do not contain fragment F30. Variable posttranslational modification (myristoylation and phosphorylatIOn) could 
account for the multiple bands. 
SDS (see Section 2), the same 68-kDa band was produced, 
indicating that the sites of glycosylation were accessible in the 
native conformation. When COX-2 was treated with endogly-
cosidase in non-denaturing buffers, the enzyme did not loose 
activity (results not shown). 
We developed a peptide map of purified COX-2 in order to 
probe for structural details. Lys-C protease was theoretically 
capable of hydrolyzing COX-2 into 35 fragments (Table 2, right 
side). Of these, 22 would be > lO amino acids in length and 6 
would contain tryptophan residues. When analysed by C4-
reverse-phase HPLC using various gradients, up to 20 frag-
ments were resolved and -8 were fluorescent indicative of the 
presence of tryptophan (Fig. 3). Through a combination ofUV 
and fluorescent absorption, mass spectral analysis, amino acid 
analysis and peptide sequencing, 15 of these fragments were 
identified. A summary of the identification of these fragments 
is indicated in Table 2 (left side). As can be seen, several of the 
fragments were the result of incomplete digestion yielding non-
terminal fragments. 
The sequence of COX-2 predicts the existence of four poten-
tial glycosylation sites (Table 2) referred to as GP 1-4 corre-
sponding to glycosylation at Asn-53, Asn-130, Asn-396 and 
Asn-580. In order to detect glycopeptides, a comparison was 
made of COX-2 either treated or untreated with endoglycosi-
dase F to remove N-linked carbohydrate structures. When Lys-
C peptide maps from native enzyme were compared to enzyme 
treated with endoglycosidase F (not shown) one broad peak 
(band G of Fig. 3) was found to shift to a faster running 
doublet. These peaks were confirmed both by mass spectral 
analysis and peptide sequencing as the F6 (sequence lO7-135) 
and F6/7 (sequence lO7-137) fragments, corresponding to de-
glycosylated glycopeptides from GP2. At present, we do not 
have conclusive evidence for or against glycosylation of GPl, 
3 or 4 (see Section 4). Because glycopeptide bands tend to be 
heterogeneous, they may be too diffuse to resolve as clear 
peaks. 
Similar peptide mapping strategies allowed the identification 
of the site of modification by [3H]aspirin as Ser-5l6. COX-2 was 
treated either with aspirin alone or with aspirin + flurbiprofen. 
When enzyme samples were desalted and then passed through 
a C4 reverse-phase column to purify COX-2 (not shown), 30-
fold more radioactivity was found in the aspirin-treated sample 
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Fig. 3. Lys-C protease peptide map of COX-2. A peptide map of 
purified COX-2 was performed with Lys-C as described in SectIOn 2. 
The peptide,; were separated by reverse-phase HPLC on an Altech C4 
column. AbsorptIOn of the peptide bond was followed (bottom) by 
absorbence at 210 nm and by fluorescent (transfer from excited trypto-
phan and tyrosllle) by monitoring at 350 nm (top). Peaks were collected. 
analysed and identified as descnbed III Table 2. 
compared to the aspirin + flubiprofen sample, indicating a 
high degree of specific labeling. Incorporation of specific label 
was estimated to occur at 70% of the enzyme monomers (aver-
age of three experiments 70% ± 4% SEM). The protein was 
further analysed by peptide mapping (Fig. 3) and individual 
peaks counted for radioactivity. The results are presented in 
Table 3. The Lys-Pro bond between F28 and F29 apparently 
resists protease cleavage because free F29 was never detected. 
Instead the longer F28/F29 peptide was found and this peptide, 
present as a series of related peaks, were found to be highly 
enriched in radioactivity. Since each of these peaks contain 
Ser-516, the amino acid analogous to the aspirin site of COX-I 
and since the only other serine (F28/29, Ser-474) was not radio-
active when sequenced (not shown), it is concluded that the 
analogous serine is acetylated in COX-2 as in COX-I. Compar-
ing the labeling of F32 to F28/29, both of which contain two 
serine residues, the specificity of labeling into Ser-516 can be 
estimated to be > 400 to I. The molecular difference between 
the various Ser-516-containing peptides in Table 3 (peptides M, 
o and R) is not clear but may be due to variable posttransla-
tional modification, such as phosphorylation or myristoylation. 
Kinetic analysis of recombinant COX-2 was performed using 
both oxygen consumption and peroxidase assays with generally 
good agreement. As indicated in Table 4, recombinant COX-2 
has kinetic properties similar to native COX-I and COX-2. 
Extent assays using limiting substrate demonstrated the lllcor-
poration of two molecules of oxygen/molecule of arachidonic 
acid substrate (not shown). Various fatty acid substrates were 
utilized by COX-2 with different efficiencies and the order of 
substrate preference was close to that expected for COX-I 
(manuscript, in prep.). The addition of heme IS essential to 
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attain COX-2 enzyme activity as measured either with cycloox-
ygenase or peroxidase assays. 
4. Discussion 
The development of isoform-specific inhibitors is theoreti-
cally possible and yet very few isoenzyme-specific inhibitors 
have been described. In contrast, numerous examples of spe-
cific inhibitors of receptor isotypes exist, such as agents which 
selectively inhibit the various adrenergic receptor subtypes. 
One reason for this contrast is that tools have not previously 
been available to pursue this goal. As one of the first cases 
where isoform-specific inhibitors are claimed, several recent 
reports [12,13,29-33] have documented selective COX-2 inhib-
itors. Presumably, other examples will follow as various targets 
are defined and evaluated at the molecular level. 
The expression and purification of human COX-2 has al-
lowed us to attempt scale-up purification and analysis of the 
recombinant COX-2 enzyme (see also [22,28,34]). COX-2 tends 
to aggregate; size-exclusion chromatography indicated the ma-
jority of the enzyme migrated as a protein dimer, however, even 
with BOG detergent in excess of its critical micellular concen-
tration, some tendency for the enzyme to form larger aggre-
gates was seen. 
When dealing with novel expression systems, the potential 
for heterogeneity of expressed protein is enormous [35]. Pro site 
analysis of the primary sequence of human COX-2 predicts 4 
potential N-Iinked glycosylation sites, 13 potential phosphoryl-
ation and 9 potential myristoylation sites. COX-I has three 
N-linked glycosylation sites all of which are glycosylated 
[14,19,36] and each of these sites are conserved in COX-2. The 
fourth site ofCOX-2 Asn-580 was shown by mutation analysis 
[36] to be incompletely glycosylated in a murine recombinant 
COX-2 expressed in COS-I cells. In the present study, Asn-130 
was shown by HPLC analysis and peptide mapping to contain 
N-Iinked carbohydrate. Although it is uncertain from the pres-
ent work whether Asn-53, Asn-396 and Asn-580 were glycosyl-
ated, from the changes in molecular weight after endoglycosi-
dase treatment, we speculate that at least two sites are glycosyl-
Table 3 
Selective labeling of Ser-516 by aspmn 
Peak number cpmJ,Ug Sequence 
A 546 
B 1088 
C 63 
D 2700 
E 0 
F 
G 
H 
I 
J 
K 
L 
M 
N 
o 
P 
Q 
R 
21 
0 
0 
299 
366 
1260 
1831 
30440 
6979 
103860 
7113 
35750 
PIDP + EMSAE 
GLMGN 
EMSAE 
EMSAE 
Assignment 
F32 
(FI8) 
F6- GP2 
F22 
FI2 
F5 or F(l8119) 
FlO, F28/29 
F30/F(?) 
F28/29 
F28/29 
The peaks shown in Fig. 3 were counted for radlOactlVlty. Essentially, 
all the radioactivity was found III peaks which included the F29 peptide 
and, therefore, exclUSively located in Ser-516 (see text). 
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Table 4 
Comparison of kinetic data for COX isoforms 
Isoform Species Km Vmdl; Spec. activity 
(uM) (nmol/min) (nmol/min/mg) 
COX-I ovine 6 100 30 
COX-2 ovme 5 90 6 
COX-2 human 3 80 25 
The expenments were conducted at 37°C in 0.1 M Tns-HCL 2 mM 
phenol, pH 7.7. The enzyme was added to start the reaction. The 
optimal velocity of oxygen was measured and used to determme the 
kinetic constants by Hanes's analysIs. 
ated in the major band (> 90% of detergent extracted material). 
The inactive COX-2 68K band which is not extracted by BOG 
detergent may represent enzyme which was not properly folded 
because it did not enter the posttranslational modification path-
way upon protein synthesis and, therefore, was not glycosyl-
ated and further modified. 
Aspirin modified Ser-S16 of COX-2, a residue which corre-
sponds to Ser-S30 of COX-l [14,19]. The results support the 
concept that the two isoforms are structurally similar. A similar 
result was found when heme binding was investigated. Careful 
titration of the enzyme resulted in a one-to-one titration of 
enzyme monomers with added heme (ses also [26,37]). Cycloox-
ygenase and peroxidase activities of the recombinant enzyme 
were carefully evaluated after heme reconstitution. The enzyme 
showed similar kinetic properties to ovine COX-l and the same 
substrate preference as COX-I. COX-2 oxygen consumption 
activity is inhibited by aspirin with a change in formation of 
IS-HETE as recently demonstrated [20,22]. 
With this body of evidence for similarity of structural and 
kinetic data between COX-l and COX-2, coupled with the near 
identity of amino acids lining the substrate binding and cata-
lytic site, it would appear to be a difficult task to exploit molec-
ular differences between the two enzymes. Interes!ingly, pro-
posed isoform-specific agents have revealed different kinetics 
of inhibition. This information may indicate that subtle amino 
acid differences of a more peripheral nature along the enzyme 
binding/reaction pathway may be exploited for specific inhibi-
tor development. It is hoped that by developing a detailed 
understanding of this enzyme isoform pair, an era of isoen-
zyme-specific inhibitors may be forthcoming. 
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